These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1068296)

  • 21. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic cytapheresis].
    Wiebecke D; Gunzer U; Ullrich H; Kadar J
    Beitr Infusionsther; 1991; 28():226-32. PubMed ID: 1725627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
    Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
    Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic difficulties in osteomyelosclerosis with myeloid metaplasia in relation to the other components of the myeloproliferative syndrome].
    Vilcu A; Hossu T; Popescu ID; Câmpeanu L
    Med Interna (Bucur); 1973 Mar; 25(3):363-76. PubMed ID: 4527026
    [No Abstract]   [Full Text] [Related]  

  • 25. [MYELOPROLIFERATIVE DISORDERS].
    MARCIACQ ALTAFULLA
    Arch Med Panamenos; 1963 Aug; 12():149-59. PubMed ID: 14164997
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic granulocytic leukaemia.
    Baikie AG
    Med J Aust; 1974 Jul; 2(1):12-7. PubMed ID: 4528473
    [No Abstract]   [Full Text] [Related]  

  • 27. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera.
    Lawler SD
    Clin Haematol; 1980 Feb; 9(1):159-74. PubMed ID: 6768481
    [No Abstract]   [Full Text] [Related]  

  • 28. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA; Pop VP; Seriakov AP
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan.
    Comhaire F; Van Hove W; Van Ganse W; Van der Straeten M
    Scand J Respir Dis; 1972; 53(5):265-73. PubMed ID: 4508954
    [No Abstract]   [Full Text] [Related]  

  • 32. [Leukemia in pregnancy (case report)].
    Schneider B
    Z Arztl Fortbild (Jena); 1973 Jan; 67(2):86-7. PubMed ID: 4512670
    [No Abstract]   [Full Text] [Related]  

  • 33. [Recent developments in the treatment of chronic myeloid leukemia].
    Herrmann R
    Med Klin; 1980 Aug; 75(18):645-9. PubMed ID: 6106883
    [No Abstract]   [Full Text] [Related]  

  • 34. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
    Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
    Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASES].
    DEGTIAREVA MM
    Probl Gematol Pereliv Krovi; 1963 Aug; 8():30-6. PubMed ID: 14091615
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The treatment of myelo-proliferative syndromes].
    Bousser J
    Sem Ther; 1965; 41(6):349-52. PubMed ID: 5234604
    [No Abstract]   [Full Text] [Related]  

  • 39. Myeloproliferative diseases in childhood.
    Nix WL; Fernbach DJ
    Am J Pediatr Hematol Oncol; 1981; 3(4):397-407. PubMed ID: 6174053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Blood coagulation and fibrinolysis in chronic myeloproliferative syndromes].
    Takahashi K; Shibata A
    Rinsho Ketsueki; 1980 May; 21(5):577-86. PubMed ID: 6997548
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.